MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-09-2022
Clovis Oncology Depreciation & Amortization 2011-2026 | CLVS
Annual Depreciation & Amortization Clovis Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 8.5 M | 8.2 M | 7.77 M | 4.6 M | 2.5 M | 1.14 M | 761 K | 444 K | 250 K | 353 K | 185 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.5 M | 185 K | 3.15 M |
Quarterly Depreciation & Amortization Clovis Oncology
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 5.71 M | 3.83 M | 1.92 M | - | 6.5 M | 4.48 M | 2.24 M | - | 6.15 M | 4.13 M | 2.13 M | - | 5.73 M | 3.63 M | 1.72 M | - | 2.5 M | 1.51 M | 586 K | - | 1.91 M | 1.28 M | 639 K | - | 819 K | 550 K | 270 K | - | 548 K | 351 K | 169 K | - | 3.7 M | 3.56 M | 3.48 M | - | 185 K | 123 K | 62 K | - | 269 K | 176 K | 84 K | - | 133 K | 86 K | 42 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.5 M | 42 K | 1.98 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
30 K | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
VistaGen Therapeutics
VTGN
|
150 K | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
3.87 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | Canada |
 |
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
16 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
259 K | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
546 K | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
129 K | - | - | $ 40.5 M | USA |
 |
Summit Therapeutics
SMMT
|
146 K | $ 16.58 | -3.94 % | $ 12.4 B |  Britain |
 |
Zymeworks
ZYME
|
3.74 M | $ 24.18 | -2.07 % | $ 1.25 B | Canada |
 |
AbbVie
ABBV
|
762 M | $ 209.4 | -0.83 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
18.4 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
Altimmune
ALT
|
112 K | $ 3.02 | -5.63 % | $ 266 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.21 | -6.2 % | $ 309 M | Britain |
 |
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Aytu BioScience
AYTU
|
5.38 M | $ 2.6 | -2.8 % | $ 16.3 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
363 K | $ 4.29 | -3.6 % | $ 822 M | Canada |